|
1 |
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
Enthalten in Nature medicine 29.4.2025: 1
|
|
|
|
2 |
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
Enthalten in Nature medicine 9.4.2025: 1-10
|
|
|
3 |
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
Marcu, Ana. - Würzburg : Universität Würzburg, 2024
|
|
|
|
4 |
Multi-omics analysis of overexpressed tumor-associated proteins: gene expression, immunopeptide presentation, and antibody response in oropharyngeal squamous cell carcinoma, with a focus on cancer-testis antigens
Abou Kors, Tsima. - Augsburg : Universität Augsburg, 2024
|
|
|
|
5 |
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors
Marcu, Ana. - Würzburg : Universität Würzburg, 2024
|
|
|
|
6 |
DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts
Goyal, Ashish. - Freiburg : Universität, 2023
|
|
|
|
7 |
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination
Mühlenbruch, Lena. - Augsburg : Universität Augsburg, 2023
|
|
|
|
8 |
Designing a SARS-CoV-2 T-cell-inducing vaccine for high-risk patient groups
Rammensee, Hans-Georg. - Freiburg : Universität, 2021
|
|
|
|
9 |
Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors
Marcu, Ana. - Augsburg : Universität Augsburg, 2021
|
|
|
|
10 |
Use of novel insertion sites for the development of polyvalent ORFV D1701-V vectored vaccines
Salomon, Ferdinand. - Tübingen : Universitätsbibliothek Tübingen, 2021
|
|
Administration
